Amneal Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
UPDATE: Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 2c, Revenues Miss; Offers FY21 Revenues Outlook
May 7, 2021 6:09 AM EDT(Updated - May 7, 2021 6:10 AM EDT)
Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Revenue for the quarter came in at $493 million versus the consensus estimate of $513.24 million.
Amneal delivered solid first quarter results, continuing our positive momentum as... More
